TSE:ONC Oncolytics Biotech (ONC) Stock Price, News & Analysis C$0.82 +0.05 (+6.49%) As of 04/29/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Oncolytics Biotech Stock (TSE:ONC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oncolytics Biotech alerts:Sign Up Key Stats Today's RangeC$0.78▼C$0.8450-Day RangeC$0.70▼C$1.0952-Week RangeC$0.67▼C$2.08Volume39,300 shsAverage Volume98,256 shsMarket CapitalizationC$63.20 millionP/E RatioN/ADividend Yield0.31%Price TargetC$3.50Consensus RatingN/A Company OverviewOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Read More… Oncolytics Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreONC MarketRank™: Oncolytics Biotech scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.0 / 5Analyst RatingN/A Amount of Analyst CoverageOncolytics Biotech has received no research coverage in the past 90 days.Read more about Oncolytics Biotech's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncolytics Biotech is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncolytics Biotech is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncolytics Biotech has a P/B Ratio of 6.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ONC. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldOncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthOncolytics Biotech does not have a long track record of dividend growth.Read more about Oncolytics Biotech's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ONC. News and Social Media0.6 / 5News SentimentN/A Search Interest3 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oncolytics Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.82% of the stock of Oncolytics Biotech is held by insiders.Percentage Held by InstitutionsOnly 1.75% of the stock of Oncolytics Biotech is held by institutions.Read more about Oncolytics Biotech's insider trading history. Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address ONC Stock News HeadlinesBuzz on the Bullboards: Energy, cannabis, and Biotech Shine on the TSXApril 17, 2025 | msn.comSmall-cap cancer therapy innovator raises $20M in flexible fundingApril 11, 2025 | msn.comTop performing AI play of the decade…? (The answer will shock you)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.April 30, 2025 | Timothy Sykes (Ad)Oncolytics Biotech Inc.March 24, 2025 | wsj.comOncolytics Biotech: Continuing To Justify The NegativityMarch 11, 2025 | seekingalpha.comOncolytics price target lowered to C$5 from C$6 at RBC CapitalMarch 10, 2025 | markets.businessinsider.comOncolytics Biotech Inc.: Oncolytics Biotech Reports Highlights and Financial Results for Q4 and Year-End 2024March 7, 2025 | finanznachrichten.deFrom Clinical Trials to the Market: Cancer Stocks With Big Potential in 2025March 7, 2025 | baystreet.caSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? Oncolytics Biotech's stock was trading at C$1.33 at the beginning of 2025. Since then, ONC stock has decreased by 38.3% and is now trading at C$0.82. View the best growth stocks for 2025 here. How were Oncolytics Biotech's earnings last quarter? Oncolytics Biotech Inc. (TSE:ONC) posted its earnings results on Tuesday, November, 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01. How do I buy shares of Oncolytics Biotech? Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Oncolytics Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Ballard Power Systems (BLDP), (ONCYF) (ONCYF), Resverlogix (RVX), Birchcliff Energy (BIR), Enbridge (ENB) and Barrick Gold (GOLD). Company Calendar Last Earnings11/12/2024Today4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolTSE:ONC CIKN/A Webwww.oncolyticsbiotech.com Phone+1-403-6707380FaxN/AEmployees29Year FoundedN/APrice Target and Rating Average Stock Price TargetC$3.50 High Stock Price TargetC$3.50 Low Stock Price TargetC$3.50 Potential Upside/Downside+326.8%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-27,662,548.23 Net MarginsN/A Pretax MarginN/A Return on Equity-141.94% Return on Assets-71.33% Debt Debt-to-Equity Ratio11.75 Current Ratio2.99 Quick Ratio8.86 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.19 per share Price / Cash Flow4.22 Book ValueC$0.12 per share Price / Book6.97Miscellaneous Outstanding Shares77,074,100Free FloatN/AMarket CapC$63.20 million OptionableNot Optionable Beta1.35 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (TSE:ONC) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Silent Heist Draining Your Retirement SavingsU.S. Debt Crisis - A Silent Heist of Your Retirement Savings Americans are losing wealth daily and don't ev...American Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.